Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26643382 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL17033096 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL17031894 | 0.87 | CHRM2 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL26112972 | 0.84 | EPHX1 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL26112977 | 0.84 | EPHX1 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL19616822 | 0.84 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL1579022 | 0.84 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL5142783 | 0.84 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL24189702 | 0.80 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HPGDEPHX1 | |
| SCHEMBL25276005 | 0.77 | CHRM2 (0.38) | CHRM2CHRM1CHRM3HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| EP-4688776-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | Acerta Pharma B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA BV (NL) | 2025-11-27 | — | — | US | disclosed |
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4497751-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceuticals Co., Ltd. (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-119317628-A | Substituted bridged ring inhibitors and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119173518-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119173253-A | Combination of allosteric and orthosteric EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | ACERTA PHARMA B.V. (NL) | 2024-10-10 | — | — | US | disclosed |
| WO-2024201240-A1 | 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN | ACERTA PHARMA B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3256463-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | HSD17B10 2586/4885CHRM2 1678/4885CHRM1 2358/4885 |
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, WEE1, NRAS | HSD17B10 1467/4885CHRM2 4876/4885CHRM1 4856/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | HSD17B10 3811/4885CHRM2 723/4885CHRM1 365/4885 |
| US-20240335431-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | HSD17B10 3464/4885CHRM2 234/4885CHRM1 49/4885 |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | TRPA1, TRPV1, TRPV5 | HSD17B10 2586/4885CHRM2 1678/4885CHRM1 2358/4885 |
| US-20250360112-A1 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | MEN1, PKD1, ADCYAP1R1 | HSD17B10 3464/4885CHRM2 234/4885CHRM1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.